MinervaX is a Danish biotech company developing a maternal vaccine to prevent life-threatening infections in newborns. The vaccine seeks to avoid Group B streptococcus (“GBS”) bacteria responsible for infant deaths, stillbirths, and severe disabilities in children globally.
GBS bacteria the leading cause of life-threatening bacterial infection in newborns, causing infant mortality and stillbirth as well as severe pregnancy complications for the mother
Disproportionately affects low- and middle-income countries
Increasing AMR: Prophylactic antibiotics treatment offered to women at risk, driving antimicrobial resistance
SDG #3.1 – Reduce maternal mortality Potential contribution: Reduce preventable deaths caused by GBS infection in pregnant mothers
SDG # 3.2: End all preventable deaths under 5 years of age Potential contribution: Reduce preventable deaths caused by GBS infection in newborns
SDG #3.3 – Fighting communicable diseases Potential contribution: Reduction of GBS infections and combating antimicrobial resistance
SDG #3.b – support R&D, and universal access to affordable vaccines and medicines Potential contribution: Affordable vaccine that allows for global distribution through established procurement and distribution mechanisms